In preliminary studies, iberdomide reduced Ikaros and Aiolos expression in SLE B cells, while inhibiting antibody production and differentiation of B cells into plasmablasts.27 Iberdomide has undergone a phase I study, which explored the effects of oral administration in healthy volunteers and confirmed the reduction of Ikaros and Aiolos at protein level in B cells, T cells and monocytes.28 Iberdomide also inhibited anti-dsDNA and antiphospholipid antibody production ex vivo from SLE mononuclear cells. The gene discussed is IKZF3; the disease is systemic lupus erythematosus.